ArticleClinical rheumatology2026
Assessing disease activity in polymyalgia rheumatica using the systemic immune-inflammation index: A retrospective cross-sectional study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolymyalgia rheumatica (PMR) is an inflammatory rheumatic condition predominantly affecting older individuals, characterized by pain and stiffness in the shoulder and pelvic girdles. The PMR Activity Score (PMR-AS) is a composite tool for assessing disease activity, yet easily accessible inflammatory biomarkers that correlate with disease activity remain limited. The Systemic Immune-Inflammation Index (SII), derived from peripheral blood counts has emerged as a novel marker reflecting systemic inflammation.
objectiveTo investigate the relationship between the SII index and disease activity as measured by the PMR-AS in patients diagnosed with PMR.
methodsIn this retrospective cross-sectional study, 180 patients diagnosed with PMR were included. Clinical and laboratory data at diagnosis were analyzed. PMR-AS was calculated at baseline. Pretreatment complete blood counts were used to determine the SII index. The association between SII index and PMR-AS was evaluated using Pearson correlation analysis. Patients were stratified into low disease activity and moderate-high disease activity groups based on a PMR-AS cut-off of 7. Multivariate linear regression was conducted to evaluate the independent association between SII index and PMR-AS.
resultsAmong 180 patients with PMR, 86 (47.8%) had moderate-high disease activity. Coronary artery disease (CAD) was significantly more common in this group. Patients with moderate-high disease activity showed elevated WBC and neutrophil counts, reduced lymphocyte counts, and higher CRP levels. The SII index was markedly higher in the moderate-high disease activity group and demonstrated a moderate correlation with PMR-AS (r = 0.47). In multivariate analysis, CAD and SII index were independent predictors of moderate-high disease activity. ROC analysis confirmed that SII index demonstrated acceptable discriminatory performance moderate-high disease activity.
conclusionThe SII index may reflect disease activity in PMR and could be considered a non-invasive, cost-effective adjunct to clinical evaluation. Key Points • The SII index is a powerful predictor of disease activity in PMR. • Presence of CAD and higher SII index were independently associated with moderate-high disease activity, highlighting systemic inflammation. • Routine assessment of SII index may improve disease monitoring in PMR, supporting its integration into clinical evaluation alongside established disease activity scores.
Indexed as
Identifiers
41830994What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.